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Background
Breast cancer is a common malignant tumour prevalent in
Ireland and rest of the world. Although breast cancer
screening and treatment has dramatically improved
patient prognosis, it is still the leading cause of cancer-
related death for women. One of the major bases for
breast cancer treatment is patient’s receptor status: ER,
PR, HER2 positive or negative. Immunohistochemistry
(IHC) is a technique that diagnoses abnormal cells, which
uses antibodies to detect antigens (proteins) of interest in
a biological tissue. IHC is widely used in hospitals and
laboratories, for screening patient receptor status. In this
study, IHC was performed on breast tumour samples
obtained at Beaumont Hospital to assess 3 protein biomar-
kers Ki67, HOXC10 and HOXC11. Aim: This study aimed
to use IHC technique to: 1. Optimize HOXC11 staining
for use on TMA (Tissue MicroArray) 2. Assess Ki67 stain-
ing in a pre-stained TMA 3. Stain full face sections from
primary and matched metastatic tissue for HOXC10.
Methods
To perform Immunohistochemistry, 3 stages were carried
out: TMA preparation, Antigen Retrieval and DAKO
staining. The stained tissue samples were scored using
Allred Scoring System (for HOXC10 and HOXC11) and
Aperio Imagescope (for Ki67) to determine positivity and
intensity of its stain. Each patient was then categorised
into stain-positive and stain-negative groups, as the binary
input data for analysis. Stata 10 software program was
used to compare protein profile of the patients with
already-existing patient database which also contains
information on patient prognosis. Wilcoxon statistical
analysis was performed to compare patient outcome based
on patient receptor status and protein profile.
Results
1. HOXC11 staining was successful, but inconsistent.
2. HOXC10 is expressed in primary breast tumour;
however this expression is lost in matched metastatic
tissue. 3. Ki67 positive patients have faster tumour
recurrence (p=0.0051). 4. Luminal breast cancer type
(ER+ve, PR +ve/-ve and HER2-ve) with positive Ki67
status have faster tumour recurrence (p=0.0004).
Conclusions
1. HOXC11 staining optimization is required for a robust
staining protocol. Investigating efficacy of other antigen
retrieval methods is required such as using a pressure coo-
ker. 2. HOXC10 expression was reduced in metastatic
breast cancer, which corroborates findings in the Oesterrich
lab [1] 3. Ki67 positive status was shown to be associated
with faster tumour recurrence and its sub-categorization of
Luminal type is agreement with Hughes et al [2] IHC opti-
mization is important for robust understanding of new pro-
teins in cancer, which may help improve personalized
medicine and enhance optimal treatment even further.
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